Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 4
2021 5
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-infiltrating lymphocytes in the immunotherapy era.
Paijens ST, Vledder A, de Bruyn M, Nijman HW. Paijens ST, et al. Cell Mol Immunol. 2021 Apr;18(4):842-859. doi: 10.1038/s41423-020-00565-9. Epub 2020 Nov 2. Cell Mol Immunol. 2021. PMID: 33139907 Free PMC article. Review.
Antigen-specific active immunotherapy for ovarian cancer.
Paijens ST, Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, de Bruyn M, Nijman HW. Paijens ST, et al. Cochrane Database Syst Rev. 2018 Sep 10;9(9):CD007287. doi: 10.1002/14651858.CD007287.pub4. Cochrane Database Syst Rev. 2018. PMID: 30199097 Free PMC article. Review.
Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients.
Paijens ST, Vledder A, Loiero D, Duiker EW, Bart J, Hendriks AM, Jalving M, Workel HH, Hollema H, Werner N, Plat A, Wisman GBA, Yigit R, Arts H, Kruse AJ, de Lange NM, Koelzer VH, de Bruyn M, Nijman HW. Paijens ST, et al. Oncoimmunology. 2021 Jun 6;10(1):1935104. doi: 10.1080/2162402X.2021.1935104. Oncoimmunology. 2021. PMID: 34123576 Free PMC article.
First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.
Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de Bruyn M, Schuuring E, Regts J, Marra R, Werner N, Sluis J, van der Zee AGJ, Wilschut JC, Allersma DP, van Zanten CJ, Kosterink JGW, Jorritsma-Smit A, Yigit R, Nijman HW, Daemen T. Komdeur FL, et al. Among authors: paijens st. Mol Ther. 2021 Feb 3;29(2):611-625. doi: 10.1016/j.ymthe.2020.11.002. Epub 2020 Nov 5. Mol Ther. 2021. PMID: 33160073 Free PMC article. Clinical Trial.
FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW, Roze JF, Peters EDJ, Sereno F, Brink AGJ, Paijens ST, Nijman HW, van Meurs HS, van Lonkhuijzen LRCW, Piek JMJ, Lok CAR, Monroe GR, van Haaften GW, Zweemer RP. Groeneweg JW, et al. Among authors: paijens st. Gynecol Oncol. 2021 Aug;162(2):413-420. doi: 10.1016/j.ygyno.2021.05.027. Epub 2021 Jun 1. Gynecol Oncol. 2021. PMID: 34083028 Free article.
Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup.
Roze J, Monroe G, Kutzera J, Groeneweg J, Stelloo E, Paijens S, Nijman H, Meurs HV, Lonkhuijzen LV, Piek J, Lok C, Jonges G, Witteveen P, Verheijen R, Haaften GV, Zweemer R. Roze J, et al. Among authors: paijens s. Cancers (Basel). 2020 May 21;12(5):1308. doi: 10.3390/cancers12051308. Cancers (Basel). 2020. PMID: 32455687 Free PMC article.
In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors.
Roze J, Sendino Garví E, Stelloo E, Stangl C, Sereno F, Duran K, Groeneweg J, Paijens S, Nijman H, van Meurs H, van Lonkhuijzen L, Piek J, Lok C, Jonges G, Witteveen P, Verheijen R, van Haaften G, Zweemer R, Monroe G. Roze J, et al. Among authors: paijens s. Cancers (Basel). 2021 Jan 20;13(3):368. doi: 10.3390/cancers13030368. Cancers (Basel). 2021. PMID: 33498451 Free PMC article.
Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.
Brunekreeft KL, Paijens ST, Wouters MCA, Komdeur FL, Eggink FA, Lubbers JM, Workel HH, Van Der Slikke EC, Pröpper NEJ, Leffers N, Adam J, Pijper H, Plat A, Kol A, Nijman HW, De Bruyn M. Brunekreeft KL, et al. Among authors: paijens st. Oncoimmunology. 2020 May 13;9(1):1760705. doi: 10.1080/2162402X.2020.1760705. Oncoimmunology. 2020. PMID: 32923120 Free PMC article.